About Supernus Pharmaceuticals
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 25 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
In 2013, we launched Oxtellar XR (oxcarbazepine) extended-release and Trokendi XR (topiramate) extended-release, our two novel treatments for patients with epilepsy. In 2017, we also launched Trokendi XR as a novel treatment for the prophylaxis of migraine. In addition, we are developing multiple product candidates in psychiatry to address significant unmet medical needs for the treatment of Impulsive Aggression (IA), attention deficit hyperactivity disorder (ADHD), depression and bipolar.